CD4 and myeloid sarcoma: While some have reported that the expression of CTLA-4 is decreased in MS patients compared with HCs [53,54,55], others have found no significant difference [56,57,58], while Kosmaczewska et al. [59] reported an increased median percentage of freshly isolated peripheral blood CD4+ CTLA-4+ T cells in MS patients.